Castle Biosciences, Inc.

NasdaqGM:CSTL Voorraadrapport

Marktkapitalisatie: US$834.9m

Castle Biosciences Beheer

Beheer criteriumcontroles 4/4

De CEO Castle Biosciences is Derek Maetzold, benoemd in Sep2007, heeft een ambtstermijn van 17.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.61M, bestaande uit 42.7% salaris en 57.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.43% van de aandelen van het bedrijf, ter waarde $ 11.92M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 4 jaar.

Belangrijke informatie

Derek Maetzold

Algemeen directeur

US$1.6m

Totale compensatie

Percentage CEO-salaris42.7%
Dienstverband CEO17.2yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn4.3yrs
Gemiddelde ambtstermijn bestuur4yrs

Recente managementupdates

Recent updates

Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Oct 15
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?

Castle Biosciences: Inflection Into Profitability

Aug 16

Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Aug 11
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts

Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 08
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Aug 04
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up

Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Jul 12
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?

Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13
Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Castle Biosciences Q2 2022 Earnings Preview

Aug 08

Analyse CEO-vergoeding

Hoe is Derek Maetzold's beloning veranderd ten opzichte van Castle Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$6m

Jun 30 2024n/an/a

-US$3m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$2mUS$686k

-US$57m

Sep 30 2023n/an/a

-US$76m

Jun 30 2023n/an/a

-US$89m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$8mUS$660k

-US$67m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$7mUS$625k

-US$31m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$5mUS$550k

-US$10m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

US$7m

Mar 31 2020n/an/a

US$6m

Dec 31 2019US$4mUS$770k

US$3m

Sep 30 2019n/an/a

US$4m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$791kUS$410k

-US$10m

Compensatie versus markt: De totale vergoeding ($USD 1.61M ) Derek } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.17M ).

Compensatie versus inkomsten: De vergoeding van Derek is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Derek Maetzold (62 yo)

17.2yrs

Tenure

US$1,605,984

Compensatie

Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Derek Maetzold
Founder17.2yrsUS$1.61m1.43%
$ 11.9m
Frank Stokes
CFO & Treasurer6.9yrsUS$880.25k0.11%
$ 918.8k
Kristen Oelschlager
Chief Operating Officer4.3yrsUS$828.48k0.48%
$ 4.0m
Tobin Juvenal
Chief Commercial Officer4.3yrsUS$829.10k0.20%
$ 1.7m
Camilla Zuckero
Vice President of Investor Relations & Corporate Affairsno datageen gegevensgeen gegevens
Kevin Doman
Vice President of Sales2.4yrsgeen gegevensgeen gegevens
Keli Greenberg
VP of Human Resources & Executive Director of Human Resources4.3yrsgeen gegevensgeen gegevens
Matthew Goldberg
Senior Vice President of Medical1.5yrsgeen gegevensgeen gegevens
Bernhard Spiess
Company Secretaryno dataUS$1.69mgeen gegevens

4.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CSTL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Derek Maetzold
Founder17.2yrsUS$1.61m1.43%
$ 11.9m
Daniel Bradbury
Independent Chairman of the Board12.2yrsUS$305.95k0.078%
$ 651.1k
G. Cole
Independent Director5.9yrsUS$289.20k0.047%
$ 396.2k
Tiffany Olson
Independent Director3.5yrsUS$279.20k0.062%
$ 513.7k
Kenneth Aldape
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Howard Colman
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Kimberlee Caple
Independent Director3.3yrsUS$276.70k0.049%
$ 410.9k
Miles Harrison
Independent Director4.6yrsUS$285.45k0.047%
$ 396.2k
Ellen Goldberg
Independent Director3.3yrsUS$274.20k0.066%
$ 553.9k
Rodney Cotton
Independent Directorless than a yeargeen gegevensgeen gegevens

4.0yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CSTL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).